William Blair Issues Pessimistic Outlook for CRBP Earnings

Key Points

• William Blair has lowered its Q3 2026 EPS estimates for Corbus Pharmaceuticals, forecasting a loss of ($1.87) per share, a decrease from the previous estimate of ($1.55).
• Corbus's current full-year earnings consensus estimate is a loss of ($4.23) per share, with projected losses increasing to ($7.02) EPS for FY2026 and ($10.88) EPS for FY2027.
• Despite the pessimistic outlook, Corbus Pharmaceuticals has recently seen a stock price surge of 342% YTD and a market cap of approximately $237.26 million.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - Equities researchers at William Blair lowered their Q3 2026 earnings per share (EPS) estimates for Corbus Pharmaceuticals in a research report issued on Monday, October 20th. William Blair analyst A. Hsieh now anticipates that the biopharmaceutical company will post earnings per share of ($1.87) for the quarter, down from their prior forecast of ($1.55). The consensus estimate for Corbus Pharmaceuticals' current full-year earnings is ($4.23) per share. William Blair also issued estimates for Corbus Pharmaceuticals' Q4 2026 earnings at ($2.15) EPS, FY2026 earnings at ($7.02) EPS and FY2027 earnings at ($10.88) EPS.

Corbus Pharmaceuticals (NASDAQ:CRBP - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.44) earnings per share for the quarter, beating analysts' consensus estimates of ($1.55) by $0.11.

A number of other brokerages have also recently weighed in on CRBP. Oppenheimer dropped their price target on Corbus Pharmaceuticals from $56.00 to $53.00 and set an "outperform" rating for the company in a research report on Wednesday, August 6th. Piper Sandler restated an "overweight" rating and issued a $51.00 price target on shares of Corbus Pharmaceuticals in a research report on Monday. B. Riley upgraded Corbus Pharmaceuticals to a "strong-buy" rating and set a $28.00 price objective for the company in a research report on Wednesday, July 30th. HC Wainwright reiterated a "buy" rating and set a $40.00 price objective on shares of Corbus Pharmaceuticals in a research report on Monday. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Corbus Pharmaceuticals in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $45.86.

Corbus Pharmaceuticals Stock Up 5.9%

Shares of CRBP stock opened at $19.36 on Wednesday. Corbus Pharmaceuticals has a fifty-two week low of $4.64 and a fifty-two week high of $20.77. The stock has a market cap of $237.26 million, a P/E ratio of -4.07 and a beta of 2.84. The business has a fifty day simple moving average of $12.02 and a 200-day simple moving average of $9.23.

Institutional Trading of Corbus Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Assenagon Asset Management S.A. purchased a new stake in Corbus Pharmaceuticals in the 3rd quarter valued at about $1,080,000. Bank of America Corp DE grew its holdings in Corbus Pharmaceuticals by 333.6% in the 2nd quarter. Bank of America Corp DE now owns 71,893 shares of the biopharmaceutical company's stock valued at $496,000 after buying an additional 55,314 shares during the period. Baker Avenue Asset Management LP purchased a new stake in Corbus Pharmaceuticals in the 2nd quarter valued at about $138,000. Marshall Wace LLP purchased a new stake in Corbus Pharmaceuticals in the 2nd quarter valued at about $137,000. Finally, Corton Capital Inc. purchased a new stake in Corbus Pharmaceuticals in the 2nd quarter valued at about $86,000. Hedge funds and other institutional investors own 64.64% of the company's stock.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.